Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B

Bibliography

• Andreoli TE. On the anatomy of amphotericin B-cholesterol pores in lipid bilayer membranes. Kidney Int 1973;4:337-45
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Marr K, Rex J, Cohen S. Amphotericin B: time for a new “gold standard”. Clin Infect Dis 2003;37(3):415-25
   PubMed Web of Science ®Google Scholar
• Fungizone for infusion [package insert]. Squibb, New York; 1959
   Google Scholar
• Kleinberg M. What is the current and future status of conventional amphotericin B? Int J Antimicrob Agents 2006;27S:S12-16
   Web of Science ®Google Scholar
• AmBisome (amphotericin B) liposome for injection. [package insert]Gilead Sciences; San Dimas, CA: 2012
   Google Scholar
• Rex J, Stevens D. Systemic antifungal agents. In: Mandell G, Bennett J, Dolin R, editors. Mandell, douglas, and Bennett's principles and practice of infectious diseases. 7th edition. Churchill Livingstone Elsevier; Philadelphia, PA: 2009. p. 549-63
   Google Scholar
• Adler-Moore JP, Proffitt RT. Amphotericin b lipid preparations: what are the differences? Clin Microbiol Infect 2008;14(Suppl 4):25-36
   PubMed Web of Science ®Google Scholar
• Hamill RJ. Amphotericin b formulations: a comparative review of efficacy and toxicity. Drugs 2013;73:919-34
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Natarajan-Arne S, Nivoix Y, Letscher-Bru V. The lipid formulations of amphotericin B. Expert Opin Pharmacother 2003;4(8):1277-87
   PubMed Web of Science ®Google Scholar
• Andes D, Safdar N, Marchillo K, Conklin R. Pharmacokinetic-pharmacodynamic comparison of amphotericin b (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother 2006;50(2):674-84
   PubMed Web of Science ®Google Scholar
• Bekersky I, Fielding RM, Dressler DE, et al. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin b (AmBisome) and amphotericin b deoxycholate in humans. Antimicrob Agents Chemother 2002;46(3):828-33
   PubMed Web of Science ®Google Scholar
• Adler-Moore JP, Proffitt RT. Ambisome: long circulating liposomal formulation of amphotericin B. In: Woodle MC, Storm G, editors. Long-circulating liposomes: old drugs, new therapeutics. Springer-Verlag; New York, NY: 1998. p. 185-206
   Google Scholar
• Adler-Moore JP, Proffitt RT. Development, characterization, efficacy and mode of action of ambisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res 1993;3(3):429-50
   Google Scholar
• Bekersky I, Fielding RM, Dressler DE, et al. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 2002;46(3):834-40
   PubMed Web of Science ®Google Scholar
• Bellman R, Egger P, Wiedermann C. Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence. Clin Infect Dis 2003;36(11):1500-1
   PubMed Web of Science ®Google Scholar
• Brajtburg J, Elberg S, Bolard J, et al. Interaction of plasma proteins and lipoproteins with amphotericin B. J Infect Dis 1984;149(6):986-97
   PubMed Web of Science ®Google Scholar
• Walsh T, Goodman J, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001;45(12):3487-96
   PubMed Web of Science ®Google Scholar
• Wasan K, Lopez-Berestein G. Modification of amphotericin B's therapeutic index by increasing its association with serum high-density lipoproteins. Ann N Y Acad Sci 1994;730:93-106
   PubMed Web of Science ®Google Scholar
• Wasan K, Lopez-Berestein G. The interaction of liposomal amphotericin B and serum lipoproteins within the biological milieu. J Drug Target 1994;2:373-80
   PubMed Web of Science ®Google Scholar
• Bekersky I, Boswell GW, Hiles R, et al. Safety, toxicokinetics, and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats. Pharm Res 2000;17:1494-502
   PubMed Web of Science ®Google Scholar
• Wasan K, Lopez-Berestein G. Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients. Clin Infect Dis 1996;23(5):1126-38
   PubMed Web of Science ®Google Scholar
• Legrand P, Vertut-Doi A, Bolard J. Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line. J Antimicrob Chemother 1996;37(3):519-33
   PubMed Web of Science ®Google Scholar
• Mehta R, Poddar S, Kalidas M, et al. Role of macrophages in the candidacidal activity of liposomal amphotericin B. J Infect Dis 1997;175(1):214-17
   PubMed Web of Science ®Google Scholar
• Walsh T, Yeldandi V, McEvoy M, et al. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 1998;42(9):2391-8
   PubMed Web of Science ®Google Scholar
• van Etten E, ten Kate M, Snijders S, Bakker-Woudenberg I. Administration of liposomal agents and blood clearance capacity of the mononuclear phagocyte system. Antimicrob Agents Chemother 1998;42(7):1677-81
   PubMed Web of Science ®Google Scholar
• Baginski M, Sternal K, Czub J, Borowski E. Molecular modeling of membrane activity of amphotericin B, a polyene macrolide antifungal antibiotic. Acta Biochim Pol 2005;52(3):655-8
   PubMed Web of Science ®Google Scholar
• Romero E, Valdivieso E, Cohen B. Formation of two different types of ion channels by amphotericin B in human erythrocyte membranes. J Membr Biol 2009;230:69-81
   PubMed Web of Science ®Google Scholar
• Dotis J, Simitsopoulou M, Dalakiouridou M, et al. Effects of lipid formulations of amphotericin B on activity of human monocytes against Aspergillus fumigatus. Antimicrob Agents Chemother 2006;50(3):868-73
   PubMed Web of Science ®Google Scholar
• De Kruijff B, Demel RA. Polyene antibiotic-sterol interactions in membranes of acholeplasma laidlawii cells and lecithin liposomes. III. Molecular structure of the polyene antibiotic-cholesterol complexes. Biochim Biophys Acta 1974;339:57-70
   PubMed Web of Science ®Google Scholar
• Cohen BE. Amphotericin B membrane action: role for two types of ion channels in eliciting cell survival and lethal effects. J Membr Biol 2010;238:1-20
   PubMed Web of Science ®Google Scholar
• Hsu S, Burnette R. The effect of amphotericin B on the K-channel activity of MDCK cells. Biochim Biophys Acta 1993;1152:189-91
   PubMed Web of Science ®Google Scholar
• Hsu S, Burnette R. Characterization of the effects of amphotericin B on ion channels in MDCK cells using the patch-clamp technique. Biochim Biophys Acta 1997;1329:26-38
   PubMed Web of Science ®Google Scholar
• Baran M, Borowski E, Mazerski J. Molecular modeling of amphotericin B-ergosterol primary complex in water II. Biophys Chem 2009;141:162-8
   PubMed Web of Science ®Google Scholar
• Brutyan RA, McPhie P. On the one-sided action of amphotericin B on lipid bilayer membranes. J Gen Physiol 1996;107:69-78
   PubMed Web of Science ®Google Scholar
• Neumann A, Baginski M, Czub J. How do sterols determine the antifungal activity of amphotericin B? Free energy of binding between the drug and its membrane targets. J Am Chem Soc 2010;132(51):18266-72
   PubMed Web of Science ®Google Scholar
• Gray KC, Palacios DS, Dailey I, et al. Amphotericin primarily kills yeast by simply binding ergosterol. Proc Natl Acad Sci USA 2012;109(7):2234-9
   PubMed Web of Science ®Google Scholar
• Palacios D, Anderson T, Burke M. A post-PKS oxidation of amphotericin B skeleton predicted to be critical for channel formation is not required for potent antifungal activity. J Am Chem Soc 2007;129(45):13804-5
   PubMed Web of Science ®Google Scholar
• Phillips A, Sudbery I, Ramsdale M. Apoptosis induced by environmental stresses and amphotericin B in candida albicans. Proc Natl Acad Sci USA 2003;100(24):14327-32
   PubMed Web of Science ®Google Scholar
• Mousavi S, Robson G. Oxidative and amphotericin B-mediated cell death in the opportunistic pathogen aspergillus fumigatus is associated with an apoptotic-like phenotype. Microbiology 2004;150(6):1937-45
   PubMedGoogle Scholar
• Al-Dhaheri RS, Douglas LJ. Apoptosis in candida biofilms exposed to amphotericin B. J Med Mcirobiol 2009;59(2):149-57
   PubMed Web of Science ®Google Scholar
• Shaha C. Apoptosis in Leishmania species & its relevance to disease pathogenesis. Indian J Med Res 2006;123(3):233-44
   PubMed Web of Science ®Google Scholar
• Bernardi P, Rasola A. Calcium and cell death: the mitochondrial connection. Subcell Biochem 2007;45:481-506
   PubMedGoogle Scholar
• Sokol-Anderson M, Brajtburg J, Medoff G. Amphotericin B-induced oxidative damage and killing of candida albicans. J Infect Dis 1986;154(1):76-83
   PubMed Web of Science ®Google Scholar
• Blum G, Perkhofer S, Haas H, et al. Potential basis for amphotericin B resistance in aspergillus terreus. Antimicrob Agents Chemother 2008;52(4):1553-5
   PubMed Web of Science ®Google Scholar
• Lamy-Freund M, Ferreira V, Schreier S. Mechanism of inactivation of the polyene antibiotic amphotericin B. Evidence for radical formation in the process of autooxidation. J Antibiot (Tokyo) 1985;38(6):753-7
   PubMed Web of Science ®Google Scholar
• Sangalli-Leite F, Scorzoni L, Mesa-Arango A, et al. Amphotericin B mediates killing in cryptococcus neoformans through the induction of a strong oxidative burst. Microbes Infect 2011;13:457-67
   PubMed Web of Science ®Google Scholar
• Proffitt R, Satorius A, Chiang S, et al. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother 1991;28(Suppl B):49-61
   PubMed Web of Science ®Google Scholar
• Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity: a review. J Chemother 2000;12(6):463-70
   PubMed Web of Science ®Google Scholar
• Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32(5):686-93
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764-71
   PubMed Web of Science ®Google Scholar
• Safdar A, Ma J, Saliba F, et al. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine 2010;89(4):236-44
   PubMed Web of Science ®Google Scholar
• Noguchi S, Takahashi N, Ito M, et al. Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged neutropenia. Int J Clin Oncol 2012; [Epub ahead of print] Available from: http://www.ncbi.nlm.nih.gov/pubmed/23076821
   Web of Science ®Google Scholar
• Shigemi A, Matsumoto K, Ikawa K, et al. Safety analysis of liposomal amphotericin B in adult patients: anaemia, thrombocytopenia, nephrotoxicity, hepatotoxicity and hypokalaemia. Int J Antimicrob Agents 2011;38:417-20
   PubMed Web of Science ®Google Scholar
• Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000;31(5):1155-63
   PubMed Web of Science ®Google Scholar
• Wasan K, Brocks D, Lee S, et al. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat Rev Drug Discov 2008;7(1):84-99
   PubMed Web of Science ®Google Scholar
• Wasan K, Morton R, Rosenblum M, Lopez-Berestein G. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. J Pharm Sci 1994;83(7):1006-10
   PubMed Web of Science ®Google Scholar
• Wasan K, Rosenblum M, Cheung L, Lopez-Berestein G. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob Agents Chemother 1994;38(2):223-7
   PubMed Web of Science ®Google Scholar
• Groll AH, Muller FC, Piscitelli SC, Walsh TJ. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer. Klin Padiatr 1998;210(4):265-73
   Google Scholar
• Lee J, Amantea M, Francis P, et al. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother 1994;38(4):713-18
   PubMed Web of Science ®Google Scholar
• Andreoli TE, Monahan M. The interaction of polyene antibiotics with thin lipid membranes. J Gen Physiol 1968;52(2):300-25
   PubMed Web of Science ®Google Scholar
• Mehta R, Lopez-Berestein G, Hopfer R, et al. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta BBABiomembr 1984;770(2):230-4
   PubMed Web of Science ®Google Scholar
• Sperry P, Cua D, Wetzel S, Adler-Moore J. Antimicrobial activity of AmBisome and non-liposomal amphotericin B following uptake of Candida glabrata by murine epidermal Langerhans cells. Med Mycol 1998;36(3):135-41
   PubMed Web of Science ®Google Scholar
• Adler-Moore J, Proffitt R. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002;49(Suppl 1):21-30
   PubMed Web of Science ®Google Scholar
• Butler WT, Hill GJ II, Szwed CF, Knight V. Amphotericin B renal toxicity in the dog. J Pharmacol Exp Ther 1963;143:47-56
   Web of Science ®Google Scholar
• Bullock WE, Luke RG, Nuttall CE, Bhathena D. Can mannitol reduce amphotericin B nephrotoxicity? Double-blind study and description of a new vascular lesion in kidneys. Antimicrob Agents Chemother 1976;10(3):555-63
   PubMed Web of Science ®Google Scholar
• Bhathena DB, Bulllock WE, Nuttall CE, Luke RG. The effects of amphotericin B therapy on the intrarenal vasculature and renal tubules in man. A study of biopsies by light, electron and immunofluorescence microscopy. Clin Nephrol 1978;9(3):103-10
   PubMed Web of Science ®Google Scholar
• Sabra R, Branch RA. Amphotericin B nephrotoxicity. Drug Saf 1990;5(2):94-108
   PubMed Web of Science ®Google Scholar
• Gerkens JF, Branch RA. The influence of sodium status and furosemide on canine acute amphotericin B nephrotoxicity. J Pharmacol Exp Ther 1980;214(2):306-11
   PubMed Web of Science ®Google Scholar
• Gerkens JF, Heidemann HT, Jackson EK, Branch RA. Effect of aminophylline on amphotericin B nephrotoxicity in the dog. J Pharmacol Exp Ther 1983;244(3):609-13
   Google Scholar
• Heidemann HT, Gerkens JF, Jackson EK, Branch RA. Effect of aminophylline on renal vasoconstriction produced by amphotericin B in the rat. Naunyn Schmiedebergs Arch Pharmacol 1983;324(2):148-52
   PubMed Web of Science ®Google Scholar
• Sabra R, Takahashi K, Branch RA, Badr KF. Mechanisms of amphotericin B-induced reduction of the glomerular filtration rate: a micropuncture study. J Pharmacol Exp Ther 1990;253(1):34-7
   PubMed Web of Science ®Google Scholar
• Shahid M, Francis J, Majid DSA. Tumor necrosis factor-alpha induces renal vasoconstriction as well as natriuresis in mice. Am J Physiol Ren Physiol 2008;295(6):F1836-44
   Google Scholar
• Falk R, Hacham M, Nyska A, et al. Induction of interleukin-1beta, tumour necrosis factor-alpha and apoptosis in mouse organs by amphotericin B is neutralized by conjugation with arabinogalactan. J Antimicrob Chemother 2005;55(5):713-20
   PubMed Web of Science ®Google Scholar
• Louie A, Baltch AL, Franke MA, et al. Comparative capacity of four antifungal agents to stimulate murine macrophages to produce tumour necrosis factor alpha: an effect that is attenuated by pentoxifyline, liposomal vesicles, and dexamethasone. J Antimicrob Chemother 1994;34(6):975-87
   PubMed Web of Science ®Google Scholar
• Sawaya BP, Weihprecht H, Campbell WR, et al. Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats. J Clin Invest 1991;87(6):2097-107
   PubMed Web of Science ®Google Scholar
• Blum SF, Shohet SB, Nathan DG, Gardner FH. The effect of amphotericin B on erythrocyte membrane cation permeability: its relation to in vivo erythrocyte survival. J Lab Clin Med 1969;73(6):980-7
   PubMedGoogle Scholar
• Bernardo JF, Murakami S, Branch RA, Sabra R. Potassium depletion potentiates amphotericin-B-induced toxicity to renal tubules. Nephron 1995;70(2):235-41
   PubMed Web of Science ®Google Scholar
• Yano T, Itoh Y, Kawamura E, et al. Amphotericin B-induced renal tubular cell injury is mediated by Na+ Influx through ion-permeable pores and subsequent activation of mitogen-activated protein kinases and elevation of intracellular Ca2+ concentration. Antimicrob Agents Chemother 2009;53(4):1420-6
   PubMed Web of Science ®Google Scholar
• Hemstreet BA. Antimicrobial-associated renal tubular acidosis. Ann Pharmacother 2004;38:1031-8
   PubMed Web of Science ®Google Scholar
• Walev I, Bhakdi S. Possible reason for preferential damage to renal tubular epithelial cells evoked by amphotericin B. Antimicrob Agents Chemother 1996;40(5):1116-20
   PubMed Web of Science ®Google Scholar
• Gouge TH, Andriole VT. An experimental model of amphotericin B nephrotoxicity with renal tubular acidosis. J Lab Clin Med 1971;78(5):713-24
   PubMedGoogle Scholar
• Anderson CM. Sodium chloride treatment of amphotericin B nephrotoxicity: standard of care? West J Med 1995;162(4):313-17
   PubMedGoogle Scholar
• Tolins JP, Raji L. Chronic amphotericin B nephrotoxicity in the rat, protective effect of prophylactic salt loading. Am J Kidney Dis 1988;11(4):313-17
   PubMed Web of Science ®Google Scholar
• Stein RS, Alexander JA. Sodium protects against nephrotoxicity in patients receiving amphotericin B. Am J Med Sci 1989;298(5):299-304
   PubMed Web of Science ®Google Scholar
• Llanos A, Cieza J, Bernardo JF, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991;40(2):302-8
   PubMed Web of Science ®Google Scholar
• Branch RA. Prevention of amphotericin b-induced renal impairment: a review on the use of sodium supplementation. Arch Intern Med 1988;148(11):2389-94
   PubMed Web of Science ®Google Scholar
• Cleary JD, Schwartz M, Rogers PD, et al. Effects of amphotericin B and caspofungin on histamine expression. Pharmacotherapy 2003;23(8):966-73
   PubMed Web of Science ®Google Scholar
• Goodwin SD, Cleary JD, Walawander CA, et al. Pretreatment regimens for adverse events related to infusion of amphotericin B. Dis Clin Infect Dis 1995;20:755-61
   PubMed Web of Science ®Google Scholar
• Roden MM, Nelson LD, Knudsen TA, et al. Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics. Clin Infect Dis 2003;36(10):1213-20
   PubMed Web of Science ®Google Scholar
• Sau K, Mambula SS, Latz E, et al. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem 2003;278(39):37561-8
   PubMed Web of Science ®Google Scholar
• Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 1995;38:459-65
   PubMed Web of Science ®Google Scholar
• Baronti R, Masini E, Bacciottini L, Mannaioni P. Differential effects of amphotericin B and liposomal amphotericin B on inflammatory cells in vitro. Inflamm Res 2002;51:259-64
   PubMed Web of Science ®Google Scholar
• Gabizon A, Isacson R, Libson E, et al. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol (Madr) 1994;33(7):779-86
   PubMed Web of Science ®Google Scholar
• Olson F, Mayhew E, Maslow D, et al. Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur J Cancer Clin Oncol 1982;18(2):167-76
   PubMedGoogle Scholar
• Szebeni J, Fontana JL, Wassef NM, et al. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-c5a antibody. Circulation 1999;99(17):2302-9
   PubMed Web of Science ®Google Scholar
• Levine SJ, Walsh TJ, Martinez A, et al. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med 1991;114(8):664-6
   PubMed Web of Science ®Google Scholar
• Burks LC, Aisner J, Fortner CL, Wiernik PH. Meperidine for the treatment of shaking chills and fever. Arch Intern Med 1980;1401:483-4
   Google Scholar
• Cleary JD, Chapman SW, Nolan RL. Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells. Antimicrob Agents Chemother 1992;36(5):977-81
   PubMed Web of Science ®Google Scholar
• Tynes BS, Utz JP, Bennett JE, Alling DW. Reducing amphotericin B reactions: a double blind study. Am Rev Respir Dis 1963;87:264-8
   PubMed Web of Science ®Google Scholar
• Yeo E, Ryu J, Cho Y, et al. Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood 2006;107:916-23
   PubMed Web of Science ®Google Scholar
• Hoeprich PD. Clinical use of amphotericin B and derivatives: lore, mystique, and fact. Clin Infect Dis 1992;14(Suppl 1):S114-19
   Web of Science ®Google Scholar
• Hamill RJ, Sobel JD, El-Sadr W, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis 2009;51(2):225-32
   Web of Science ®Google Scholar
• Brandiss MW, Wolff SM, Moores R, Stohlman F. Anemia induced by amphotericin B. JAMA 1964;189(9):663-6
   PubMed Web of Science ®Google Scholar
• Lin A, Goldwasser E, Bernard E, Chapman S. Amphotericin B blunts erythropoietin response to anemia. J Infect Dis 1989;161:348-51
   Web of Science ®Google Scholar
• MacGregor R, Bennett J, Erslev A. Erythropoietin concentration in amphotericin B-induced anemia. Antimicrob Agents Chemother 1978;14(2):270-3
   PubMed Web of Science ®Google Scholar
• Mahmud H, Mauro D, Quadri S, et al. Triggering of suicidal erythrocyte death by amphotericin B. Cell Physiol Biochem 2009;24:263-70
   PubMed Web of Science ®Google Scholar
• Slisz M, Cybulska B, Mazerski J, et al. Studies of the effects of antifungal cationic derivatives of amphotericin B on human erythrocytes. J Antibiot (Tokyo) 2004;57(10):669-78
   PubMed Web of Science ®Google Scholar
• Burke D, Lal R, Finkel KW, et al. Acute amphotericin B overdose. Ann Pharmacother 2006;40:2254-9
   PubMed Web of Science ®Google Scholar
• Wang GS, Banerji S, Roussil TK, Heard KJ. Survival after amphotericin B overdose treated with plasmapheresis. Ann Pharmacother 2013;47(2):e9
   Google Scholar
• Larabi M, Yardley V, Loiseau PM, et al. Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B. Antimicrob Agents Chemother 2003;47(12):3774-9
   PubMed Web of Science ®Google Scholar
• Jensen G, Skenes C, Bunch T, et al. Determination of the relative toxicity of amphotericin B formulations: a red blood cell potassium release assay. Drug Deliv 1999;6(2):81-8
   Web of Science ®Google Scholar
• Charvalos E, Tzatzarakis MN, Van Bambeke F, et al. Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects. J Antimicrob Chemother 2005;57(2):236-44
   PubMed Web of Science ®Google Scholar
• Chan C, Tuazon C, Lessin L. Amphotericin-B-induced thrombocytopenia. Ann Intern Med 1982;96(3):332-3
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in india. N Engl J Med 2010;362:504-12
   PubMed Web of Science ®Google Scholar
• Sloand E, Kumar P, Yu M, Klein H. Effect of amphotericin B and fluconazole on platelet membrane glycoproteins. Transfusion 1994;34(5):415-20
   PubMed Web of Science ®Google Scholar
• Kulpa J, Zaroulis C, Good R, Kutti J. Altered platelet function and circulation induced by amphotericin B in leukemic patients after platelet transfusion. Transfusion 1981;21(1):74-6
   PubMed Web of Science ®Google Scholar
• Hussein M, Fletcher R, Long T, et al. Transfusion platelets 2h after the completion of amphotericin-B decreases its detrimental effect on transfused platelet recovery and survival. Transfus Med 1998;8:43-7
   PubMed Web of Science ®Google Scholar
• Miller M. Reversible hepatotoxicity related to amphotericin B. Can Med Assoc J 1984;131:1245-7
   PubMed Web of Science ®Google Scholar
• Wingard JR, Leather H. Hepatotoxicity associated with antifungal therapy after bone marrow transplantation. Clin Infect Dis 2005;41:301-7
   PubMedGoogle Scholar
• Olin JL, Spooner LM. Amphotericin B-associated hyperbilirubinemia: case report and review of the literature. Pharmacotherapy 2006;26(7):1011-17
   PubMed Web of Science ®Google Scholar
• Fischer MA, Winkelmayer WC, Rubin RH, Avorn J. The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Clin Infect Dis 2005;41(3):301-7
   PubMed Web of Science ®Google Scholar
• Fleming RV, Kantarjian HM, Husni R, et al. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001;40(5-6):511-20
   PubMed Web of Science ®Google Scholar
• Chamilos G, Luna M, Lewis R, et al. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study. Clin Ther 2007;29(9):1980-6
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Gamaletsou MN, McGinnis MR, et al. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis 2012;54(Suppl 1):S55-60
   PubMed Web of Science ®Google Scholar
• Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013;56(12):1724-32
   PubMed Web of Science ®Google Scholar
• Gamaletsou MN, Daikos G, Walsh TJ, et al. Phenotypic and molecular resistance patterns of Candida species in patients with candidemia and hematologic malignancies [abstract O465]. Programme of the 23rd European Congress for Clinical Microbiology and Infectious Diseases (ECCMID); 2013
   Google Scholar
• Denning DW, Perlin DS. Azole resistance in Aspergillus: a growing public health menace. Future Microbiol 2011;6(11):1229-32
   PubMed Web of Science ®Google Scholar
• Wilcock BC, Endo MM, Uno BE, Burke MD. C2′–OH of amphotericin B plays an important role in binding the primary sterol of human cells but not yeast cells. J Am Chem Soc 2013;135(23):8488-91
   PubMed Web of Science ®Google Scholar
• Leenders AC, Reiss P, Portegies P, et al.Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997;11(12):1463-71
   PubMed Web of Science ®Google Scholar
• Ng TT, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections: evaluation of United Kingdom compassionate use data. Arch Intern med 1995;155:1093-8
   PubMed Web of Science ®Google Scholar